Fan Mu

Education
Ph.D., epidemiology, Harvard University; M.S., epidemiology, Harvard University; M.B.B.S., medicine, Peking University
Summary of Experience
Dr. Mu specializes in the application of advanced epidemiologic methodologies and biostatistical techniques to address a wide array of analytical questions in health care involving evaluation, decision making, and strategy. She has broad experience designing and implementing advanced and innovative data analytics and solutions for life sciences companies. Dr. Mu’s expertise includes real-world evidence development, database analyses, chart review studies, survey research, predictive analytics, systematic and targeted literature reviews, indirect comparisons, and health economic modeling. She has broad experience developing strategies and conducting research to assess the clinical, economic, and humanistic impacts of diseases and treatments in a range of therapeutic areas, including nephrology, immunology, psychiatry, oncology, dermatology, gynecology, and virology. She has consulted to numerous life sciences companies on both novel pipeline agents and products on the market. Dr. Mu’s work has supported health care payers and clinical decision makers in both US and global markets. Her research has been published in peer-reviewed journals and presented at clinical and economic research conferences.
-
Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Journal of the American Heart Association, 2025
2025Agiro A, Mu F, Cook E, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desai P, Chertow GM
HEOR, Epidemiology & Market Access -
Hyperkalemia and Risk of Chronic Kidney Disease Progression: A Propensity Score Matched Analysis
Kidney360, 2024
2024Agiro A, Cook E, Mu F, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desa P, Chertow GM
HEOR, Epidemiology & Market Access -
Economic burden of recurrent hyperkalemia in patients with chronic kidney disease
Journal of Managed Care & Specialty Pharmacy, 2024
2024Bakris G, Agiro A, Greatsinger A, Mu F, Cook EE, Sundar M, Louden E, Colman E, Desai P
HEOR, Epidemiology & Market Access -
Real-World Effectiveness of Benralizumab Among Patients with Asthma and Concomitant Chronic Obstructive Pulmonary Disease
International Journal of Chronic Obstructive Pulmonary Disease, 2024
2024Carstens DD, Maselli DJ, Cook EE, Mu F, Chen J, Yang D, DeMartino JK , Chung Y
HEOR, Epidemiology & Market Access -
Descriptive Analysis of Types and Diagnoses Associated with Lower Extremity Amputation: Analysis of the US Veterans Health Administration Database 2019-2023
Advances in Therapy, 2024
2024Lal B, Gao C, Mu F, Chen G, Hua Q, Calish J, Parker M
HEOR, Epidemiology & Market Access -
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database
Cancers, 2024
2024Kaplan DE, Tan R, Xiang C, Mu F, Hernandez S, Ogale S, Li J, Lin Y, Shi L, Singal AG
HEOR, Epidemiology & Market Access -
Real-World Effectiveness of Omadacycline and Impact of Unapproved Omadacycline Prescription Claims among Adult Outpatients with Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections
Journal of Managed Care & Specialty Pharmacy, 2023
2023Lodise TP, Gunter K, Mu F, Gao E, Yang D, Yim E, Sandor S, Berman G
HEOR, Epidemiology & Market Access -
Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The Optimize I Study
Advances in Therapy, 2023
2023Agiro A, Amin AN, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV
HEOR, Epidemiology & Market Access -
Impact on Hospitalizations of Long-Term Versus Short-Term Therapy with Sodium Zirconium Cyclosilicate During Routine Outpatient Care of Patients with Hyperkalemia: The Recognize I Study
Expert Review of Pharmacoeconomics and Outcomes Research, 2023
2023Pollack CV, Agiro A, Mu F, Cook EE, Wirtz EL, Young JA, Betts KA, Brahmbhatt YG
HEOR, Epidemiology & Market Access -
Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study
Journal of Medical Economics, 2023
2023Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D
HEOR, Epidemiology & Market Access -
Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study
Annals of Allergy, Asthma & Immunology, 2022
2022Chung Y, Katial R, Mu F, Cook E, Young J, Yang D, Betts K, Carstens D
HEOR, Epidemiology & Market Access -
Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
Advances in Therapy, 2022
2022Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO
HEOR, Epidemiology & Market Access -
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
Advances in Therapy, 2022
2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ
HEOR, Epidemiology & Market Access -
The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): A retrospective cohort study
Clinical Endocrinology, 2022
2022Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO
HEOR, Epidemiology & Market Access -
Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
Advances in Therapy, 2022
2022Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S
HEOR, Epidemiology & Market Access -
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
HEOR, Epidemiology & Market Access -
Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease
Advances in Therapy, 2022
2022Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, Yang H, Azimi N, Strand V, Yarur A
HEOR, Epidemiology & Market Access -
The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases
Advances in Therapy, 2022
2022Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, Yang H, Downes N, Azimi N, Strand V
HEOR, Epidemiology & Market Access -
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
HEOR, Epidemiology & Market Access -
Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record Analysis
Advances in Therapy, 2022
2022Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ
HEOR, Epidemiology & Market Access -
Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control Study
International Journal of Endocrinology, 2022
2022Gosmanova EO, Ayodele O, Chen K, Cook EE, Mu F, Young JA, Rejnmark L
HEOR, Epidemiology & Market Access -
Inpatient Management and Post-Discharge Outcomes of Hyperkalemia
Hospital Practice, 2021
2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K
HEOR, Epidemiology & Market Access -
Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort
European Congress of Endocrinology, 2021
2021Gosmanova EO, Ayodele O, Sherry N, Mu F, Briggs A, Swallow E, Rejnmark L
HEOR, Epidemiology & Market Access -
Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support
Clinical Nutrition ESPEN, 2021
2021Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL
HEOR, Epidemiology & Market Access -
Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
Advances in Therapy, 2021
2021Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E
HEOR, Epidemiology & Market Access -
Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia
Advances in Therapy, 2021
2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ
HEOR, Epidemiology & Market Access -
The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia
Clinical Drug Investigation, 2021
2021Zichlin ML, Mu F, Leo S, Ayyagari R
HEOR, Epidemiology & Market Access -
Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases
Clinical Therapeutics, 2021
2021Setyawan J, Mu F, Yarur A, Zichlin ML, Yang H, Fernan C, Billmyer E, Downes N, Azimi N, Strand V
HEOR, Epidemiology & Market Access -
Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
Advances in Therapy, 2021
2021Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, Briggs A, Sherry N, Kaul S
HEOR, Epidemiology & Market Access -
Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
Advances in Therapy, 2021
2021Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, Ayodele O, Sherry N, Ketteler M
HEOR, Epidemiology & Market Access -
Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
Advances in Therapy, 2021
2021Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, Sherry N, Rejnmark L
HEOR, Epidemiology & Market Access -
Prevalence and economic burden of hyperkalemia in the United States Medicare population
Current Medical Research and Opinion
2020Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ
HEOR, Epidemiology & Market Access -
Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia
BMC Psychiatry, 2020
2020Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B
HEOR, Epidemiology & Market Access -
Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations
Kidney International Reports, 2020
2020Betts K, Wooley J, Mu F, Wang Y, Wang Y, Dua A, Wu E
HEOR, Epidemiology & Market Access -
Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders
Journal of Medical Economics, 2020
2020Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B
HEOR, Epidemiology & Market Access -
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
Kidney Medicine, 2020
2020Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D
HEOR, Epidemiology & Market Access -
The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States
Movement Disorders. 2019 Feb;34(2):236-245
2019Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K
HEOR, Epidemiology & Market Access -
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
Journal of Parenteral and Enteral Nutrition, 2019
2019Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB
HEOR, Epidemiology & Market Access -
The prevalence of hyperkalemia in the United States
Current Medical Research and Opinion. 2018 Jun;34(6):971-978
2018Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ
HEOR, Epidemiology & Market Access -
The Cost of Hyperkalemia in the United States
Kidney Int Rep. Mar 2018;3(2):385-393
2018Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ
HEOR, Epidemiology & Market Access -
Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income
British Journal of Dermatology, 2018
2018Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J
HEOR, Epidemiology & Market Access
-
August 24, 2024
Analysis Group Researchers to Present at ISPE 2024
Event: 40th International Society for Pharmacoepidemiology (ISPE) Annual Meeting
Host: International Society for Pharmacoepidemiology (ISPE)
-
September 11, 2024
-
July 19, 2022
-
April 5, 2022
